NewsRoom Articles - Page 132 of 202

ThursdayAug 26, 2021 12:06 pm

Molecular Approaches May Help Accurately Diagnose Lesions in Drug-Resistant Focal Epilepsy

A recently published review has discovered that considering genetic data for individuals who are suffering from drug-resistant focal epilepsy has led to the definition of novel illness entities and enhanced clinical decision making. Drug-resistant focal epilepsy, as defined by the International League Against Epilepsy, usually occurs when an individual has failed to stay free of seizures with sufficient trials of 2 ASMs (anti-seizure medication). The disease is often caused by brain lesions such as glioneural tumors. These drugs must have been specifically chosen for the individual’s type of seizures and tried in combination with other seizure medications or on their…

ThursdayAug 26, 2021 10:44 am

AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) Names CEO of AnPac Bio U.S. to Drive Adoption of Early Cancer Detection Technology

Early cancer detection technology innovator AnPac Bio-Medical Science Co. Ltd. has been awarded 142 patents with 95 patents pending as part of its bid to revolutionize cancer screening protocols AnPac Bio’s proprietary technology screens for a variety of biophysical properties and analyzes the results to establish risk factors for tumor development before tumor cells begin circulating in the bloodstream AnPac Bio’s technology can be combined with the more extant tumor cell-detection technology to boost the screening’s effectiveness The international company, with operations in the US and China recently named an accomplished bio-medical executive, Dr. Sunil Pandit, as the CEO of…

WednesdayAug 25, 2021 12:31 pm

Study Looks Into Mutations That Cause Resistance to Cancer Therapies

A study conducted by researchers from UT Southwestern has discovered that mutating genes to create proteins that drive cancer using a virus may allow scientists to better understand the resistance that develops to the cancer treatments used to target them. The researchers’ findings were published in “Cancer Research,” with the scientists noting that their discovery could assist in better understanding the interaction between treatments and their target proteins, as well as in the development of treatments that bypass resistance. Dr. Ralf Kittler from the Eugene McDermott Center for Human Growth and Development, who is the research leader, stated that the…

WednesdayAug 25, 2021 11:05 am

InMed Pharmaceuticals Inc. (NASDAQ: INM) Pursues Commercial Production of Rare Cannabinoids at Pharmaceutical Levels

Canadian clinical-stage drug development company InMed Pharmaceuticals is working to achieve pharmaceutical approval of rare cannabinoids InMed Pharmaceutical has developed a trademarked platform called IntegraSyn that extracts five times the normally expected yields of cannabinoids from its plant sources IntegraSyn’s ability to increase yields may ultimately help InMed to achieve a profitable means of producing cannabinol (“CBN”) and other lesser-known cannabinoids at commercial scales To date, GW Pharma’s Epidiolex is the only cannabis-derived product to achieve FDA approval as a pharmaceutical, and the company’s multi-million-dollar revenues demonstrate the potential returns a pharmaceutical-level drug can achieve British Columbia, Canada-based InMed Pharmaceuticals…

TuesdayAug 24, 2021 12:41 pm

Nearly 30% of Suicide-Prone People Have Regained Full Psychological Well-Being

A nationally representative study that was recently conducted reports that about 29% of participants who had a suicide attempt history had achieved a state of complete mental health. In order to make that determination, participants had to report high levels of psychological and social well-being in the last month, almost daily life satisfaction or happiness in the last month, and freedom from suicidality and mental ailments such as substance dependence and psychiatric disorders to be considered in complete mental health. The study was published in the “Archives of Suicide Research.” Prof. Esme Fuller-Thomson from the University of Toronto, the study’s…

MondayAug 23, 2021 12:05 pm

ASTRO Releases Clinical Guidelines for Soft-Tissue Sarcoma Radiation in Adults

The American Society for Radiation Oncology recently released a new clinical guideline that offers guidance on the utilization of radiation therapy in the treatment of soft-tissue sarcoma patients. The new guideline was published in “Practical Radiation Oncology.” The recommendations include treatment planning, radiation techniques and optimal radiation dosing for patients with operable, localized soft-tissue sarcoma of the extremities, including legs and arms and the abdominal wall and chest wall. Soft-tissue sarcoma is rare, making up only 1% of malignancies in adults. The condition is known to be lethal and comprises more than 50 subtypes, which are all different. The tumors…

MondayAug 23, 2021 10:45 am

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Releases Q1 2021 Operational, Financial Report

Q1 2021 report notes distinction of becoming first psychedelic company to list on the NYSE American LLC stock exchange Cybin has garnered “a great deal of attention as an emerging leader in the psychedelic therapeutics space,” says CEO Several of the quarter’s highlights tied into the company’s active development of its psychedelic pipeline Cybin (NEO: CYBN) (NYSE American: CYBN) is wrapping up a highly successful first quarter with the release of its Q1 2021 operational and financial report, for the period ended June 30, 2021 (https://ibn.fm/V9xNp). The biotech company, which is focused on progressing psychedelic therapeutics, hit some milestones this quarter,…

FridayAug 20, 2021 11:08 am

Current Bladder Cancer Treatments May Adversely Affect Patients’ Psychosocial Well-Being

A study that was recently published in the “International Journal of Urological Nursing” found that intravesical therapy affected the physical, emotional and social well-being of patients who suffered from non-muscle invasive bladder cancer. The participants of the study underwent intravesical therapy together with either mitomycine (“MMC”) or Bacillus Calmette-Guerin (“BCG”) treatments. The objective of the authors of the study was to evaluate the psychosocial issues these study subjects experienced during therapy and what effects those challenges triggered. In their report, the authors stated that the patients struggled to cope with treatment side effects, adding that this was in addition to…

FridayAug 20, 2021 9:00 am

Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) 2021 Growth Strategy Update

So far in 2021, Mind Cure has embarked on an aggressive plan to strengthen its advisory board and file for new provisional patents for its fully synthetic ibogaine In January, the company also announced an amended agreement to grow the size of an earlier-announced bought deal financing This year has also seen the launch of the second stage of manufacturing of Ibogaine for use in psychedelic clinical research Mind Cure also continues to strengthen its proprietary digital therapeutics technology (“DTx”), iSTRYM All of Mind Cure’s decisions thus far are designed to help the company achieve overall growth and fulfill its vision of easing suffering, increasing productivity, and enhancing mental health Mind Cure…

ThursdayAug 19, 2021 11:23 am

Cybin Inc. (NEO: CYBN) (NYSE American CYBN) Adelia Acquisition Making Impact, Reaching Milestones

Cybin subsidiary achieved certain milestones as outlined in acquisition agreement Adelia brought numerous advantages to company Acquisition may advance “Cybin’s ability to innovate our psychedelic drug development program and diversify beyond major depressive disorder,” says CEO Cybin's (NEO: CYBN) (NYSE American CYBN) most recent acquisition, Adelia Therapeutics Inc., is already reporting success for the company (https://ibn.fm/ZtWL2). Cybin recently announced that the wholly controlled subsidiary had achieved certain milestones for the year as outlined in the acquisition agreement, resulting in Adelia shareholders receiving common shares in Cybin. Cybin closed on the acquisition of Adelia late last year, with the company noting…

News and publishing service for medical and biotechnology related companies

Contact us: 512.354.7000

Molecular Approaches May Help Accurately Diagnose Lesions in Drug-Resistant Focal Epilepsy

AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) Names CEO of AnPac Bio U.S. to Drive Adoption of Early Cancer Detection Technology

Study Looks Into Mutations That Cause Resistance to Cancer Therapies

InMed Pharmaceuticals Inc. (NASDAQ: INM) Pursues Commercial Production of Rare Cannabinoids at Pharmaceutical Levels

Nearly 30% of Suicide-Prone People Have Regained Full Psychological Well-Being

ASTRO Releases Clinical Guidelines for Soft-Tissue Sarcoma Radiation in Adults

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Releases Q1 2021 Operational, Financial Report

Current Bladder Cancer Treatments May Adversely Affect Patients’ Psychosocial Well-Being

Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) 2021 Growth Strategy Update

Cybin Inc. (NEO: CYBN) (NYSE American CYBN) Adelia Acquisition Making Impact, Reaching Milestones

Official NewsWire Relationships

BioMedWire Currently Accepts

BioMedWire

Company Search

Site Search